# Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

> **NCT03497702** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 114 (estimated)

## Conditions studied

- Breast Cancer
- Invasive Breast Cancer

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Letrozole
- **DRUG:** leuprorelin

## Key facts

- **NCT ID:** NCT03497702
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-08
- **Primary completion:** 2023-11
- **Final completion:** 2024-01
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2018-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03497702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03497702, "Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03497702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*